Nuclear factor κB subunits RelB and cRel negatively regulate Toll-like receptor 3-mediated β-interferon production via induction of transcriptional repressor protein YY1.
Jakub Siednienko, Ashwini Maratha, Shuo Yang, Malgorzata Mitkiewicz, Sinéad M Miggin, Paul N Moynagh
Index: J. Biol. Chem. 286(52) , 44750-63, (2011)
Full Text: HTML
Abstract
The induction of β-interferon (IFN-β) is a key anti-viral response to infection by RNA viruses. Virus-induced expression of IFN-β requires the co-operative action of the transcription factors IRF-3/7, NF-κB, and ATF-2/c-Jun on the IFN-β promoter leading to the orderly recruitment of chromatin remodeling complexes. Although viruses strongly activate NF-κB and promote its binding to the IFN-β promoter, recent studies have indicated that NF-κB is not essential for virus-induced expression of IFN-β. Herein, we examined the role of NF-κB in regulating IFN-β expression in response to the viral-sensing Toll-like receptor 3 (TLR3). Intriguingly pharmacological inhibition of the NF-κB pathway augments late phase expression of IFN-β expression in response to TLR3 stimulation. We show that the negative effect of NF-κB on IFN-β expression is dependent on the induction of the transcriptional repressor protein YinYang1. We demonstrate that the TLR3 ligand polyriboinosinic:polyribocytidylic acid (poly(I:C)) induces expression and nuclear translocation of YinYang1 where it interacts with the IFN-β promoter and inhibits the binding of IRF7 to the latter. Evidence is also presented showing that the NF-κB subunits c-Rel and RelB are the likely key drivers of these negative effects on IFN-β expression. These findings thus highlight for the first time a novel self-regulatory mechanism that is employed by TLR3 to limit the level and duration of IFN-β expression.
Related Compounds
Related Articles:
2015-05-01
[Brain. Behav. Immun. 46 , 192-202, (2015)]
2015-06-01
[Ann. Otol. Rhinol. Laryngol. 124 , 437-42, (2015)]
2015-09-01
[Proc. Natl. Acad. Sci. U. S. A. 112 , 11007-12, (2015)]
2012-02-01
[J. Neurosci. Res. 90(2) , 388-98, (2011)]
2012-03-01
[Oral Oncol. 48(3 , 226-32, (2011)]